Does DOAC treatment reduce the risk of SSE in patients with left ventricular thrombi compared with warfarin?
In patients with left ventricular thrombi, off-label use of DOACs is associated with a higher risk of stroke or systemic embolism compared to warfarin, challenging the assumption of their equivalence.
In this multicenter cohort study of anticoagulation strategies for LV thrombi, DOAC treatment was associated with a higher risk of SSE compared with warfarin use, even after adjustment for other factors. These results challenge the assumption of DOAC equivalence with warfarin for LV thrombi and highlight the need for prospective randomized clinical trials to determine the most effective treatment strategies for LV thrombi.
Robinson et al. (Wed,) studied this question.